MARKET

CATB

CATB

Catabasis Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.800
-0.030
-0.78%
After Hours: 3.730 -0.07 -1.84% 16:30 04/03 EDT
OPEN
3.820
PREV CLOSE
3.830
HIGH
3.910
LOW
3.720
VOLUME
52.12K
TURNOVER
--
52 WEEK HIGH
9.76
52 WEEK LOW
2.740
MARKET CAP
68.01M
P/E (TTM)
-1.6127
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CATB stock price target is 37.50 with a high estimate of 60.00 and a low estimate of 15.00.

EPS

CATB News

More
  • Edited Transcript of CATB earnings conference call or presentation 10-Mar-20 12:30pm GMT
  • Thomson Reuters StreetEvents · 03/27 02:40
  • Catabasis Pharmaceuticals to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference
  • Business Wire · 03/25 13:00
  • Catabasis: Worth A Look Ahead Of Phase III Data
  • Seeking Alpha - Article · 03/24 22:15
  • Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies
  • ACCESSWIRE · 03/24 21:00

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About CATB

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.
More

Webull offers kinds of Catabasis Pharmaceuticals Inc stock information, including NASDAQ:CATB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CATB stock news, and many more online research tools to help you make informed decisions.